Medicine and Dentistry
Breast Cancer
100%
Retrospective Cohort Study
51%
Metastatic Breast Cancer
51%
Malignant Neoplasm
35%
Overall Survival
34%
Palbociclib
32%
Primary Tumor
32%
Progression Free Survival
31%
Oncology
26%
Cohort Analysis
20%
Cancer Research
18%
Quality of Life
18%
Systemic Therapy
16%
Cancer Therapy
16%
Survivorship in Cancer Care
16%
Tattoo
16%
Breast Cancer Surgery
16%
Medical Oncology
16%
Fulvestrant
16%
Pertuzumab
16%
Assisted Reproductive Technology
16%
BRCA1
16%
Diarrhea
16%
Exanthem
16%
Remote Patient Monitoring
16%
Germ Cell
16%
Neoadjuvant Chemotherapy
12%
Patient-Reported Outcome
11%
Neoplasm
10%
Socioeconomic Status
9%
Cancer Diagnosis
8%
Tumor Localization
8%
Tattooing
8%
Non Invasive Procedure
8%
Survival Rate
6%
Adverse Event
6%
Propensity Score Matching
6%
Docetaxel
6%
Hazard Ratio
6%
Cancer Registry
5%
Proportional Hazards Model
5%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
34%
Palbociclib
32%
Cohort Study
32%
Progression Free Survival
31%
Overall Survival
26%
Metastatic Breast Cancer
18%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
18%
Pertuzumab
18%
Fulvestrant
16%
Aromatase Inhibitor
16%
Malignant Neoplasm
16%
Rash
16%
Diarrhea
16%
Anticancer Drug
16%
Statin (Protein)
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
7%
Survival Rate
6%
Adverse Event
6%
Docetaxel
6%
Disease Free Survival
5%
Nursing and Health Professions
Telemonitoring
32%
Cancer Center
18%
Breast Cancer
18%
Economic Analysis
16%
Malignant Neoplasm
12%
National Health Insurance
12%
Patient-Reported Outcome
11%
Quality of Life
6%
